Poliovirus Attenuated Strains as a Possible Candidate for Cancer Therapy Poliovirus Attenuated Strains as a Possible Candidate for Cancer Therapy
Article Sidebar
Main Article Content
Abstract
Abstract
The understanding of cancer continues to expand and with the growing urgency to find effective treatments, the discovery of medications that can disrupt the disease's aggressiveness holds immense importance. Live attenuated viral vaccines and oncolytic virotherapy offer promising avenues in cancer treatment. These vaccines and therapies work in various ways, including serving as vehicles to deliver inflammatory and immune-modulatory cytokines, presenting tumor-associated antigens, triggering "danger signals" to alter the tumor microenvironment, and selectively infecting cancer cells while sparing healthy ones. Clinical trials have explored the potential of several viruses for cancer treatment, with the genetically modified herpes virus, Talimogene laherparepvec, showing promise in melanoma treatment. The attenuated strain of Poliovirus, such as type 1 (Sabin), is known for its success in poliomyelitis vaccination and is now emerging as a novel option for cancer treatment. It employs multiple mechanisms to combat cancer, such as inducing tumor cell lysis through viral replication or the production of lethal viral proteins. Poliovirus is a prototype of the Entero-virus genus in the Picornaviridae family and is notorious for causing poliomyelitis in children due to its affinity for spinal cord motor neurons. Globally, live-attenuated (Sabin) and killed (Salk) vaccines are utilized to control Poliovirus. In conclusion, this study showed the potential of the polio vaccine as a viable option for cancer treatment, emphasizing its origin, potency against cancer, and its interaction with the immune system.
Keywords: Cancer therapy, immunity, Poliovirus, vaccine.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/